Research Study

A Double Blind Placebo Controlled Study to Evaluate the Effects of Bexagliflozin on Hemoglobin A1c in Patients With Type 2 Diabetes and Increased Risk of Cardiovascular Adverse Events
Principal Investigator 
G B John Mancini

Overview

Body Locations and Systems 
Diabetes - Type 2
Disorders and Conditions 
Diabetes Type 2
ClinicalTrials.gov# 
NCT02558296
Status 
Recruiting
Study Start/End 
Jul 6, 2016 to Aug 31, 2018
Locations 
Diamond Health Care Centre, Vancouver General Hospital
Name/Title 
Ngaire Meadows, Research Coordinator
Phone 
604-875-5575
Email Address 
ngaire.meadows2@vch.ca
Purpose of Study 

The purpose of this study is to investigate the effect of bexagliflozin in lowering hemoglobin A1c (HbA1c) levels in patients with type 2 diabetes mellitus (T2DM) and increased risk of cardiovascular adverse events.

The data from this study will be combined with the data from other bexagliflozin studies in a meta-analysis of CV safety outcomes.

Eligibility 

Visit ClinicalTrials.gov for more information. 

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific clinical research trials only. If you have specific questions which require clinical expertise, please call your primary care physician.